Philippe Pourquier was trained in pharmacy and received his Ph.D. degree in biochemistry and molecular biology from the University of Bordeaux in 1996. After a postdoctoral period at the US National Cancer Institute in Yves Pommier's laboratory, he obtained an INSERM research position and moved to the Bergonié Cancer Institute in 2001. He has acquired an expertise in the field of molecular pharmacology and more specifically in the mechanisms of action of drugs targeting DNA topoisomerases I and II and on the cellular resistance against these inhibitors. He is currently developing translational research programs aiming at identifying new predictive markers of cell sensitivity to anticancer agents for colon cancer and sarcomas. He has also developed a new approach for the identification of alternative therapies for the treatment of high grade prostate cancers based on their specific genomic profiling. He is a Member of the French Cancer Society and of the American Cancer Society since 1995.
Biography Updated on 14 August 2011